An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGal in Patients With Fabry Disease

Trial Profile

An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGal in Patients With Fabry Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Alpha galactosidase (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Greenovation Biotech
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 1 Feb 2017 to 1 Oct 2017.
    • 31 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Oct 2017.
    • 15 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top